Skip to content
Biodatica
Start free

Institut Curie

Paris, Clermont Ferrand

OncologyPhase III
Compare Sign in to watch

What changed

Study registered, no phase assigned: Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses (CIRCA-HPV)

1w agoTrial registeredJul 7, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

676 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Jan 31, 2026

    Metastatic Breast Cancer ( HER2 Negative), Unresectable Breast Cancer · RECRUITING · sponsor: Institut Curie · Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer

    ClinicalTrials.gov · NCT07193394 (opens the source filing in a new tab)

  2. Trial

    NA registered

    Jan 5, 2026

    Triple Negative Breast Cancer · RECRUITING · sponsor: Institut Curie · Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)

    ClinicalTrials.gov · NCT06225505 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    May 27, 2024

    Breast Carcinoma · RECRUITING · sponsor: Institut Curie · ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

    ClinicalTrials.gov · NCT06195709 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    Mar 27, 2024

    Triple Negative Breast Cancer · ACTIVE_NOT_RECRUITING · sponsor: Institut Curie · Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer

    ClinicalTrials.gov · NCT06175390 (opens the source filing in a new tab)

  5. Trial

    PHASE2 registered

    Dec 19, 2023

    HER2-positive Breast Cancer · RECRUITING · sponsor: Institut Curie · Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer

    ClinicalTrials.gov · NCT05955170 (opens the source filing in a new tab)

  6. Trial

    NA registered

    Dec 6, 2022

    Implanted Venous Access Device · COMPLETED · sponsor: Institut Curie · Use of Virtual Reality Mask or Music Therapy for Analgesia and Anxiolytic Purpose When Totally IVAD for Chemotherapy Under Local Anesthesia

    ClinicalTrials.gov · NCT04804735 (opens the source filing in a new tab)

  7. Trial

    NA registered

    May 19, 2022

    Cancer · RECRUITING · sponsor: Institut Curie · Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4

    ClinicalTrials.gov · NCT05088395 (opens the source filing in a new tab)

  8. Trial

    PHASE2 registered

    Apr 21, 2021

    HER2-negative Metastatic Breast Cancer · TERMINATED · sponsor: Institut Curie · Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer

    ClinicalTrials.gov · NCT04720729 (opens the source filing in a new tab)

  9. Trial

    NA registered

    Jan 24, 2019

    HPV Positive Pelvic Cancer · COMPLETED · sponsor: Institut Curie · Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses (CIRCA-HPV)

    ClinicalTrials.gov · NCT03739775 (opens the source filing in a new tab)

  10. Trial

    NA registered

    Dec 1, 2010

    Solid Tumor, Adult · COMPLETED · sponsor: Institut Curie · Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology

    ClinicalTrials.gov · NCT02220556 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources